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Received 24 May 2018. Accepted 14 August 2018. 
Context: There has been concern that growth hormone (GH) treatment of children might 
increase meningioma risk. Results of published studies have been inconsistent and limited.  
Objective: To examine meningioma risks in relation to GH treatment. 
Design: Cohort study with follow-up via cancer registries and other registers. 
Setting: Population-based. 
Patients: A cohort of 10,403 patients treated in childhood with recombinant GH (r-hGH) in 5 
European countries since this treatment was first used in 1984. Expected rates from national 
cancer registration statistics. 
Main Outcome Measures: Risk of meningioma incidence. 
Results: During follow-up 38 meningiomas occurred. Meningioma risk was greatly raised in the 
cohort overall (SIR=75.4; 95% confidence interval (CI) 54.9-103.6), as a consequence of high 
risk in subjects who had received radiotherapy for underlying malignancy (SIR= 658.4; 95% CI 
460.4-941.7). Risk was not significantly raised in patients who did not receive radiotherapy. Risk 
in radiotherapy-treated patients was not significantly related to mean daily dose of GH, duration 
of GH treatment or cumulative dose of GH.  
Conclusions: Our data add to evidence of very high risk of meningioma in patients treated in 
childhood with GH after cranial radiotherapy, but suggest that GH may not affect radiotherapy-
related risk, and that there is no material raised risk of meningioma in GH-treated patients who 
did not receive radiotherapy.  
In a 5-country cohort of 10,403 patients treated with recombinant growth hormone, meningioma risk was 
greatly raised in relation to radiotherapy, but not apparently related to growth hormone. 
Introduction 
 Since 1957 growth hormone (GH) has been used to treat GH deficiency and short stature, 
initially using a human pituitary extract (p-hGH) but since 1985 using solely recombinant growth 
hormone (r-hGH). 
 GH causes increased serum concentrations of insulin-like growth factor 1 (IGF-1). IGF-1 
is antiapoptotic and mitogenic in vitro, and levels in adults have been associated in several 
studies with risks of subsequent malignancies(1). As a consequence, and because of early case-
reports and some findings in humans, there has been concern as to whether or not GH therapy 
might increase cancer risks(1, 2).  
 Meningiomas express GH receptors, and in vitro activation of the GH/IGF-1 axis 
increases the growth rate of meningiomas(3). In an in vivo model, downregulation of the 
GH/IGF-1 axis reduced meningioma growth(4). In the US Childhood Cancer Survivors Study 
cohort, second malignancy was significantly more common among GH-treated than non GH-
treated patients, and meningioma was much the most common second malignancy in the GH-
treated group, accounting for 40% of all second neoplasms(5). A UK study(6) found 
meningiomas more common in GH-treated brain-irradiated cancer patients than in matched 
brain-irradiated cancer controls, but based on small numbers, and a later analysis from the US 
cohort did not find raised meningioma risk(7). The published results, however, have been based 
on relatively small numbers – 338 GH-treated patients in the US study(7) and 110 in the only 
other analysis, in the UK(6). To analyse the risk with much greater power, we therefore analysed 
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meningioma risks in the Safety and Appropriateness of Growth Hormone Treatments in Europe 
(SAGhE) study, a large cross-European cohort study of patients treated with r-GH since 1984. 
Materials and Methods 
 The SAGhE study is a coordinated cohort study in eight European countries of patients 
treated with r-hGH at paediatric ages since such treatment was first used (1984-6, depending on 
the country), and never treated with p-hGH. Details of the assembly of the cohort and methods of 
data collection have been described previously(8). Ethics committee agreement was obtained in 
every country and for each patient either written informed consent was obtained, or the ethics 
committee stated that consent was not required. Only three patients in the cohort died from 
meningioma during follow-up, so we have only undertaken incidence analyses, not mortality 
analyses, for meningioma in this paper. Cancer incidence follow-up was via cancer registration 
and highly complete in Belgium, the Netherlands, Sweden, Switzerland and the UK, and 
therefore analyses of incidence are restricted to these countries. The cohorts were national and 
population-based, or virtually so, in Belgium, the Netherlands, Sweden and the UK and clinic-
based and sub-national in (Switzerland). We obtained data on demographic and GH-related 
variables from existing databases and from case-notes. Subjects were followed for mortality via 
national population-based registries in Belgium, the Netherlands, Sweden and the UK, and by 
municipal registers and other means in Switzerland. In all countries, follow-up was independent 
of pharmaceutical companies and in all countries the study was conducted with appropriate 
ethics committee agreement. Vital status follow-up was highly complete. We excluded from 
analysis, individuals with certain conditions that both lead to GH therapy and are themselves 
very strong predisposing factors for malignancy (e.g. Type 1 neurofibromatosis, Fanconi 
syndrome(9)). In addition, we also excluded from the cohort, subjects (n=1) whose original 
diagnosis leading to growth hormone treatment was meningioma.  
 We calculated person-years at risk of meningioma in the cohort by sex, 5 year age-group, 
single calendar year, and country, commencing on the date of first treatment with GH and ending 
at whichever occurred earliest of: diagnosis of meningioma, death, loss to follow-up, or a fixed 
end-date for each country (the date to which follow-up in that country was considered complete 
at the time the follow-up data were obtained). In Switzerland, cancer incidence follow-up was 
censored at age 16 or 21, depending on the canton, because cancer incidence data were from the 
Swiss Childhood Cancer Registry which only covered these ages. 
 Meningiomas were taken as tumours coded to ICD10 codes C70 (malignant), D32 
(benign) and D42 (uncertain and unknown behaviour) (WHO, 1992), and equivalents in ICD 9. 
Observed numbers of cancers and deaths in the cohort were compared with expectations derived 
from application of sex, age, country and year specific rates in the general population of each 
country to the person-years at risk in these categories in the cohort, to provide standardised 
incidence ratios (SIRs). Absolute excess rates (AERs) were calculated by subtracting expected 
from observed numbers of cases, dividing by person-years at risk and multiplying by 10,000. 
Trends in risk with variables such as duration of GH treatment were tested as described by 
Breslow and Day(10); p values are all 2-sided. 
 As well as analyses of risks in the cohort overall, we also analysed the data in 
subdivisions by initial diagnosis, whether radiotherapy was received, and cumulative dose, mean 
daily dose, and duration of GH treatment. To be able to explore potential surveillance bias in the 
diagnosis of meningiomas in the cohort, we endeavoured to discover from clinical sources for 
each UK patient, the pathway that had led to diagnosis of the meningioma.  
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Results 
 Of 10,786 patients recorded as treated with r-hGH in the five study countries, 257 had to 
be excluded from analysis because of lack of permission for cancer incidence follow-up or lack 
of data, and 126 because of an underlying diagnosis at high risk of cancer or an underlying 
diagnosis of meningioma as the reason for GH treatment. This left 10,403 who formed the study 
cohort. Just over half were male and four fifths were aged 5-14 years at first treatment (Table 1). 
The most common underlying diagnoses were isolated growth failure (n= 3,952), and 
malignancy (n= 1,830).  
 During follow-up 326 patients died, 175 were lost to follow-up, 38 were diagnosed with 
meningioma (30 benign, 1 malignant, and 7 of uncertain behaviour), and 9,864 survived without 
meningioma to the end of the follow-up period. A total of 154,795 person-years at risk were 
accrued, an average of 14.9 years per patient. The SIR for meningioma in the cohort overall was 
75.4 (95% CI54.9-103.6) (Table 2), and the AER was 2.4 per 10,000 (not in Table). Relative 
risks were similar in males and females, and greatly raised in the Netherlands, Sweden and the 
UK. There were no cases in Belgium and Switzerland but expecteds were small (0.04 and 0.01 
respectively) and 95% CIs included the all-country SIR. All but one of the meningiomas 
occurred in patients whose initial diagnosis was cancer (SIR=466.3 (95% CI 337.8-643.5)); the 
risk was not significantly raised in patients whose initial diagnosis was not cancer (SIR=2.4 
(95% CI 0.3-16.7)). Risks were over 300-fold raised for patients whose initial diagnoses were 
CNS tumour, haematological malignancy, or non-CNS solid tumour (Table 2). 
 We had information that 1,178 of the patients had received cranio(-spinal) radiotherapy 
(all but 13 for cancer), 3,055 had not received cranio(-spinal) radiotherapy, and for 6,170 this 
was not known. Thirty of the 38 meningiomas occurred in the cancer patients known to have 
received cranio(-spinal) radiotherapy (Table 3). The relative risk of meningioma for cancer 
patients treated with radiotherapy was over 600 (Table 3). The SIR was not related to age at first 
GH treatment time since starting treatment, or attained age. There were also no significant trends 
in risk with mean daily GH dose duration of treatment, and cumulative dose of GH. Of the 
remaining meningioma cases, 7 occurred in patients with unknown radiotherapy status 
(SIR=277.5 (95% CI 132.3-582.1); all were in Sweden, for which the databases used for this 
study did not include data on radiotherapy to allow them to be included in risk analyses, but on 
separate enquiry four had received prior radiotherapy and for three no information on this was 
available.  One meningioma occurred among patients without radiotherapy (a patient with Turner 
syndrome), for whom risk was not significantly raised. 
 Of the 22 meningiomas diagnosed incident in patients in the UK, we were able to obtain 
information on the events leading to diagnosis for 14; of these; 9 were diagnosed after 
symptomatic presentations and 5 at routine follow-up. 
Discussion 
 Our analysis of over 10,000 patients treated with GH in childhood showed meningioma 
risk over 70-fold, highly significantly, raised in this cohort compared with general population 
expectations. This was a consequence of a risk six times greater than this in the subset of patients 
who had received GH after treatment for cancer, and within these, greater risk again in the 
patients who had received cranio(-spinal) radiotherapy. Although we do not have data on 
radiotherapy dose, incidence of GH deficiency after cranial radiotherapy is dose and time 
dependent(11-13) and most of the cancer patients had brain tumours, which are usually treated 
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with 40-50 Gy(11), so we would expect that radiotherapy doses in the cohort will generally have 
been ≥40 Gy.  
 The relative risks in our cohort for meningioma are far larger than for any other tumour 
after GH treatment(9). Since ionizing radiation exposure is a well-established cause of 
meningioma(14, 15), including after radiation therapy of childhood cancers(16, 17), the 
extraordinarily large risk in our GH-treated cohort does not in itself incriminate GH. 
Comparisons of follow-up of GH-treated and untreated cancer patients in the US and UK(5, 6) 
have given some evidence of raised risk of meningioma associated with GH, although a later 
analysis from the US cohort(7) did not find raised risk. Our study had the weakness that we were 
not able to compare risks in our GH cohort directly with untreated patients, since we did not have 
data on such patients.  On the other hand, our study had the strength that we were able, unlike 
previous studies, to analyse risks in relation to dose and duration of GH treatment – critical 
variables in assessing whether there is an aetiological relationship(18). These GH variables were 
not significantly related to meningioma risk and furthermore there was no significant raised risk 
of meningioma in the 8,573 non-cancer patients in our cohort who received GH therapy. Thus 
our data, based on different variables and a far larger cohort than previously, do not support the 
hypothesis that GH treatment influences meningioma risk. We were not able to collect IGF1 data 
for the cohort, but future research would be improved by investigating, if practical, whether 
IGF1 levels during GH treatment relate to subsequent meningioma risk. We were also not able to 
analyse meningioma risks in relation to extent of, or treatment for, other pituitary deficiencies, 
but these seem unlikely to explain the meningioma risk in these patients since the majority of 
cases did not have a record of other pituitary deficiencies and only thirteen had a record of 
treatment for such deficiencies. 
 The main reason for the raised meningioma risk in the cohort is likely to be ionising 
radiation exposure. Previous cohort studies of meningioma risk after radiation exposure have 
found excess relative risks (ERRs) per Gy ranging from 0.64 to 5.1, with a summary ERR across 
studies of 1.81(15). Our relative risks are of the same order as those for ≥40 Gy exposures to the 
meninges in a large UK childhood cancer cohort(16), but several times larger than those found in 
a similar US cohort(17). 
 Meningioma is a tumour for which there is known to be a high prevalence of subclinical 
disease: on brain MRI in the general population, 0.5% of individuals aged 45-59 (the youngest 
ages studied) had incidental findings of meningioma(19). There is therefore considerable scope 
for intensive medical contacts and cerebral imaging (especially MRI) consequent on underlying 
cerebral malignancies and GH treatment in our cohort to lead to diagnosis of asymptomatic 
meningiomas that would not otherwise have been detected, or at least not at that time. Such a 
‘screening’ effect, if there is one, might be expected to operate particularly around (or indeed 
before) the time of first treatment with GH, when prevalent asymptomatic meningiomas incident 
over many years previously might come to light, and to diminish subsequently, when only newly 
incident cases would be available for detection. Our data, however, did not show diminishing 
risks with longer time since first treatment. Furthermore, among the UK cases for whom we 
could identify the pathway to diagnosis, most of the tumours were investigated because of 
symptoms (although we cannot tell, of course, whether these symptoms would not have been 
presented, or not have been investigated further, if the patient had not had a previous cerebral 
tumour and GH treatment). 
 A more subtle screening effect might have occurred if improvements in imaging 
technology over time had caused detection of some meningiomas in the cohort in recent years 
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that were already present but undetected at the time of earlier, lower sensitivity, imaging(6). This 
could have led to artefactual raised risks throughout follow-up; we do not have data to measure 
the extent, if any, of such an effect. 
 In conclusion, our data add to evidence of the very high relative risks of meningioma in 
patients treated in childhood with r-hGH after cranial radiotherapy for malignancy. Clinically it 
is important to be aware of this risk when following-up such patients. Our data and the previous 
literature on radiation effects indicate that the raised risk is mainly due to radiotherapy, although 
it may also to some extent reflect detection of asymptomatic meningiomas as a consequence of 
intensive medical surveillance and cerebral imaging in these patients. Our data also suggest, 
however, that GH treatment has not augmented further the radiotherapy-related risk. 
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Table 1. Descriptive characteristics of patients in the SAGhE cohort followed for risk of 
meningioma 
Characteristic  No. % 
Sex 
Male 5530               4517 53.2 
Female 4873               3825 46.8 
Country Belgium 1325 12.7 
 
Netherlands 1685 16.2 
 
Sweden 2822 27.1 
 
Switzerland 737 7.1 
 
UK 3834 36.9 
Age started GH treatment (years) 0-4 1130 10.9 
5-9 3632 34.9 
10-14 4834 46.5 
15-19 807 7.8 
Year started GH treatment <1990 2070 19.9 
1990-94 3976 38.2 
1995-99 2840 27.3 
≥2000 1517 14.6 
Diagnosis leading to GH treatment CNS tumour 1307 12.6 
Non CNS solid tumour 97 0.9 
Hematological malignancy 426 4.1 
Chronic renal failure and renal diseases 
139 1.3 renrenal diseases diseases 
Turner syndrome 1721 16.5 
Other syndromes and chronic diseases 1003 9.6 
Multiple pituitary hormone deficiency organic GHD 1343 12.9 
Skeletal dysplasias 286 2.8 
Isolated growth failurea 3952 38.0 
Non-classifiable 129 1.2 
Total  10403 100.0 
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aIncluding isolated growth hormone deficiency, idiopathic short stature, and small for gestational age. 
Table 2.        Risk of meningioma in the cohort in relation to sex, country of residence, and 
initial diagnosis leading to GH treatment 
 All initial diagnoses Initial diagnosis cancer Initial diagnosis non-cancer 
 n SIR (95% CI) n SIR (95% CI) n SIR (95% CI) 
Sex       
 Male 18 83.7 (52.7, 132.8)*** 18 464.9 (292.9, 737.8)*** 0 0.0 (0.0, 20.5) 
 Female 20 69.2 (44.7, 107.3)*** 19 467.6 (298.3, 733.1)*** 1 4.0 (0.6, 28.6) 
Country of residence       
 Belgium 0 0.0 (0.0, 92.2) 0 0.0 (0.0, 368.9) 0 0.0 (0.0, 92.2) 
 Netherlands 9 84.4 (43.9, 162.2)*** 9 503.4 (261.9, 967.5)*** 0 0.0 (0.0, 41.0) 
 Sweden 7 40.5 (19.3, 85.0)*** 7 385.6 (183.8, 808.8)*** 0 0.0 (0.0, 24.6) 
 Switzerland 0 0.0 (0.0, 368.9) 0 0.0 (0.0, 6148.1) 0 0.0 (0.0, 368.9) 
 UK 22 126.8 (83.5, 192.6)*** 21 593.5 (387.0, 910.3)*** 1 7.2 (1.0, 51.4) 
Diagnosis leading to GH treatment     
 CNS tumour 29 533.7 (370.9, 768.0)*** 29 533.7 (370.9, 768.0)*** - - 
 Haematological malignancy 7 319.2 (152.2, 669.5)*** 7 319.2 (152.2, 669.5)*** - - 
 Non-CNS solid tumour 1 324.1 (45.6, 2300.6)** 1 324.1 (45.6, 2300.6)** - - 
 Turner syndrome 1 9.2 (1.3, 65.0)* - - 1 9.2 (1.3, 65.0)* 
 Isolated growth failure 0 0.0 (0.0, 19.4) - - 0 0.0 (0.0, 19.4) 
 Other non-cancer 0 0.0 (0.0, 30.7) - - 0 0.0 (0.0, 30.7) 
       
Total 38 75.4 (54.9, 103.6)*** 37 466.3 (337.8, 643.5)*** 1 2.4 (0.3, 16.7) 
SIR= Standardised incidence ratio; CI= confidence interval; GH= Growth hormone; CNS= central nervous system 
*
 p<0.05 
** p<0.01 
***
 p<0.001 
Table 3. Risk of meningioma in patients whose initial diagnosis was cancer and were treated by 
radiotherapy, by age and GH treatment variables 
 
 n SIR (95% CI) 
Age started GH treatment (years) 0-4 1 1401.5 (197.4, 9949.0)** 
5-9 9 782.4 (407.1, 1503.7)*** 
10-14 19 644.7 (411.2, 1010.7)*** 
15-19 1 258.1 (36.4, 1832.1)** 
 p trend  0.21 
Time since started GH treatment 
(years) 
0-4 2 338.0 (84.5, 1351.4)*** 
5-9 2 197.5 (49.4, 789.5)*** 
10-14 14 1130.7 (669.7, 1909.2)*** 
15-19 10 857.0 (461.1, 1592.8)*** 
 
≥20 2 365.8 (91.5, 1462.5)*** 
 p trend  0.26 
Attained age (years) 0-9 0 0.0 (0.0, 12296.3) 
 
10-19 6 487.2 (218.9, 1084.3)*** 
 
20-29 21 863.5 (563.0, 1324.4)*** 
 
≥30 3 346.7 (111.8, 1074.8)*** 
 p trend  0.95 
Duration of GH treatment (years) <3 8 547.5 (273.8, 1094.7)*** 
3-5 11 587.3 (325.3, 1060.5)*** 
≥6 11 998.9 (553.2, 1803.8)*** 
 p trend  0.19 
Mean GH dose (µg/kg/day) <20 7 635.1 (302.8, 1332.2)*** 
20-9 17 805.4 (500.7, 1295.6)*** 
30-9 3 425.1 (137.1, 1318.1)*** 
≥40 1 1297.5 (182.8, 9210.9)** 
 p trend  0.92 
Cumulative GH dose (mg/kg) <25 8 511.9 (256.0, 1023.7)*** 
25-49 10 601.3 (323.6, 1117.6)*** 
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
Downloaded from https://academic.oup.com/jcem/advance-article-abstract/doi/10.1210/jc.2018-01133/5075161
by Universitätsbibliothek Bern user
on 30 August 2018
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2018  DOI: 10.1210/jc.2018-01133 
 
 
11 
50-99 11 1286.0 (712.2, 2322.1)*** 
 
≥100 0 0.0 (0.0, 4098.8) 
 p trend  0.13 
Total  30 658.4 (460.4, 941.7)*** 
SIR= Standardised incidence ratio; CI= Confidence interval; GH= Growth hormone 
* p<0.05 
**
 p<0.01 
***
 p<0.001 
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